表紙
市場調查報告書

醫藥品新興國家(Pharmerging)市場分析與預測:產品,地區(等級 I(中國),等級 II(印度,巴西,俄羅斯,南非),等級 III(阿根廷,墨西哥,波蘭,土耳其,按印尼))(2014年∼2025年)

Pharmerging Market Analysis By Product, By Region {Tier I (China), Tier II (India, Brazil, Russia, South Africa) Tier III (Argentina, Mexico, Poland, Turkey, Indonesia)}, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 600779
出版日期 內容資訊 英文 100 Pages
商品交期: 2-3個工作天內
價格
Back to Top
醫藥品新興國家(Pharmerging)市場分析與預測:產品,地區(等級 I(中國),等級 II(印度,巴西,俄羅斯,南非),等級 III(阿根廷,墨西哥,波蘭,土耳其,按印尼))(2014年∼2025年) Pharmerging Market Analysis By Product, By Region {Tier I (China), Tier II (India, Brazil, Russia, South Africa) Tier III (Argentina, Mexico, Poland, Turkey, Indonesia)}, And Segment Forecasts, 2014 - 2025
出版日期: 2017年12月04日內容資訊: 英文 100 Pages
簡介

醫藥品新興國家(Pharmerging)市場預計2025年達到2兆2,319億美元。這個市場預計由於老年人口的增加,慢性疾病的疾病負擔的增加,醫療費的增加等而受到促進。還有根據聯合國,60歲以上的人口2015年達到9億100萬人,預計2030年增加14億人,2050年到21億人。由於老年人口的增加,高血脂症,高血壓,癌症,癡呆,充血性心臟衰竭等慢性疾病的治療需求成長著。老年人口構成OTC藥的40%∼50%,處方藥市場的23%∼40%。

本報告提供醫藥品新興國家(Pharmerging)市場相關調查,市場概要,各地區/等級的市場趨勢,償付制度,生產趨勢,疾病的盛行率,疾病負擔,競爭情形,主要企業的簡介等,全面的資訊。

目錄

第1章 摘要整理

  • 市場概述

第2章 調查方法

  • 資訊採購
  • 資訊/資料分析
  • 市場結構與認證

第3章醫藥品新興國家市場趨勢

  • 市場區隔和範圍
  • 滲透與成長預測製圖:各分子類型
  • SWOT分析
  • 產業分析 - 波特的五力分析
  • 國家風險分析

第4章 醫藥品新興國家市場趨勢與預測:各地區

  • 等級 I
    • 中國
  • 等級 II
    • 印度
    • 俄羅斯
    • 巴西
    • 南非
  • 等級 III
    • 阿根廷
    • 墨西哥
    • 波蘭
    • 土耳其
    • 沙烏地阿拉伯
    • 阿爾及利亞
    • 泰國
    • 印尼
    • 埃及
    • 奈及利亞
    • 烏克蘭
    • 巴基斯坦

第5章 競爭情形

  • 策略架構
  • 企業簡介
目錄
Product Code: GVR-2-68038-256-3

The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.

Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.

The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Further Key Findings from the Study Suggest:

  • Pharmaceutical segment was the major contributor for the pharmerging market in 2016.
  • Pharmaceutical sector also recorded the fastest growth in the pharmerging industry.
  • Tier I is driving growth in the pharmerging market.
  • India among the Tier II countries is estimated to witness the fastest growth in the pharmerging industry.
  • Brazil was recorded as the major contributor for Tier II countries.
  • Among Tier III countries, Nigeria and Indonesia are estimated to be driving growth.
  • The key players include Sanofi, Pfizer Inc., AstraZeneca, GlaxoSmithKline, F.Hoffmann-La Roche, GE Healthcare, Eli Lilly, Medtronic, Johnson and Johnson, Abbott.
  • The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.

Table of Contents

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation

Chapter 3 Pharmerging Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing geriatric population
      • 3.1.1.2 Increasing healthcare expenditure
      • 3.1.1.3 Increasing chronic diseases
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Lack of insurance coverage
  • 3.2 Penetration & growth prospect mapping: Molecule type
  • 3.3 Pharmerging Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's
  • 3.5 Country Risk Analysis
    • 3.5.1 Political Risks
    • 3.5.2 Economic Risk
    • 3.5.3 Demographic Risk

Chapter 4 Pharmerging Market Regional Estimates & Trend Analysis, By Service

  • 4.1 Tier I
    • 4.1.1 Reimbursement Policy
    • 4.1.2 Manufacturing outlook
    • 4.1.3 Disease prevalence
  • 4.2 Tier II
    • 4.2.1 India
      • 4.2.1.1 Reimbursement Policy
      • 4.2.1.2 Manufacturing Outlook
      • 4.2.1.3 Disease Prevalence
    • 4.2.2 Russia
      • 4.2.2.1 Reimbursement Policies
      • 4.2.2.2 Disease Prevalence
    • 4.2.3 Brazil
      • 4.2.3.1 Reimbursement Policies
      • 4.2.3.2 Manufacturing Outlook
      • 4.2.3.3 Disease Prevalence
    • 4.2.4 South Africa
      • 4.2.4.1 Reimbursement Policies
      • 4.2.4.2 Healthcare Sector Statistics
      • 4.2.4.3 Disease Prevalence
  • 4.3 Tier III
    • 4.3.1 Argentina
      • 4.3.1.1 Reimbursement Providers
      • 4.3.1.2 Healthcare Availability
      • 4.3.1.3 Disease prevalence
    • 4.3.2 Mexico
      • 4.3.2.1 Healthcare Expenditure Trends
      • 4.3.2.2 Medical Tourism
      • 4.3.2.3 Disease Prevalence
    • 4.3.3 Poland
      • 4.3.3.1 Reimbursement Policy
      • 4.3.3.2 Healthcare Statistics and Disease Burden
    • 4.3.4 Turkey
      • 4.3.4.1 Healthcare Policies
      • 4.3.4.2 Disease Burden
    • 4.3.5 Saudi Arabia
      • 4.3.5.1 Healthcare Policies
      • 4.3.5.2 Disease Burden
    • 4.3.6 Algeria
      • 4.3.6.1 Healthcare Services Outlook
      • 4.3.6.2 Disease Burden
    • 4.3.7 Thailand
      • 4.3.7.1 Healthcare policies
      • 4.3.7.2 Disease Burden
    • 4.3.8 Indonesia
      • 4.3.8.1 Healthcare Policies
      • 4.3.8.2 Disease Burden
    • 4.3.9 Egypt
      • 4.3.9.1 Healthcare Policies
      • 4.3.9.2 Disease Burden
    • 4.3.10 Nigeria
      • 4.3.10.1 Healthcare Policies
      • 4.3.10.2 Disease Burden
    • 4.3.11 Ukraine
      • 4.3.11.1 Healthcare Policies
      • 4.3.11.2 Disease Burden
    • 4.3.12 Pakistan
      • 4.3.12.1 Healthcare Policies
      • 4.3.12.2 Disease Burden

Chapter 5 Competitive Landscape

  • 5.1 Strategy framework
  • 5.2 Company Profiles
    • 5.2.1 Sanofi
      • 5.2.1.1 Company overview
      • 5.2.1.2 Financial Performance
      • 5.2.1.3 Revenue by National Market
      • 5.2.1.4 Product benchmarking
      • 5.2.1.5 Strategic initiatives
    • 5.2.2 Pfizer Inc.
      • 5.2.2.1 Company overview
      • 5.2.2.2 Financial Performance
      • 5.2.2.3 Revenues by National Market
      • 5.2.2.4 Product benchmarking
      • 5.2.2.5 Strategic initiatives
    • 5.2.3 AstraZeneca
      • 5.2.3.1 Company overview
      • 5.2.3.2 Financial performance
      • 5.2.3.1 Revenues by National Market
      • 5.2.3.2 Product benchmarking
      • 5.2.3.3 Strategic initiatives
    • 5.2.4 GlaxoSmithKline
      • 5.2.4.1 Company overview
      • 5.2.4.2 Financial performance
      • 5.2.4.3 Revenues by National Market
      • 5.2.4.4 Product benchmarking
      • 5.2.4.5 Strategic initiatives
    • 5.2.5 F.Hoffmann-La Roche Ltd
      • 5.2.5.1 Company overview
      • 5.2.5.2 Financial performance
      • 5.2.5.3 Pharmaceutical division Revenues by National Market
      • 5.2.5.4 Diagnostics division Revenues by National Market
      • 5.2.5.5 Product benchmarking
      • 5.2.5.6 Strategic initiatives
    • 5.2.6 GE Healthcare
      • 5.2.6.1 Company overview
      • 5.2.6.2 Financial performance
      • 5.2.6.3 Revenues by National Market
      • 5.2.6.4 Product benchmarking
      • 5.2.6.5 Strategic initiatives
    • 5.2.7 Eli Lilly
      • 5.2.7.1 Company overview
      • 5.2.7.2 Financial performance
      • 5.2.7.3 Revenues by National Market
      • 5.2.7.4 Product benchmarking
      • 5.2.7.5 Strategic initiatives
    • 5.2.8 Medtronic
      • 5.2.8.1 Company overview
      • 5.2.8.2 Financial performance
      • 5.2.8.3 Revenues by National Market
      • 5.2.8.4 Product benchmarking
      • 5.2.8.5 Strategic initiatives
    • 5.2.9 Johnson and Johnson
      • 5.2.9.1 Company overview
      • 5.2.9.2 Financial performance
      • 5.2.9.3 Revenues by National Market
      • 5.2.9.4 Product benchmarking
      • 5.2.9.5 Strategic initiatives
    • 5.2.10 Abbott
      • 5.2.10.1 Company overview
      • 5.2.10.2 Financial performance
      • 5.2.10.3 Revenues by National Market
      • 5.2.10.4 Product benchmarking
      • 5.2.10.5 Strategic initiatives

List of Tables

  • 1. Pharmerging Market by Region (2014 - 2025, USD Billion)
  • 2. Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 3. Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 4. Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 5. Tier 1/China Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 6. Tier 1/China Pharmerging Pharmaceuticals Market by Exclusivity (2014 - 2025, USD Billion)
  • 7. Tier 1/China Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 8. Tier 2 Pharmerging Market by Region (2014 - 2025, USD Billion)
  • 9. Tier 2 Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 10. Tier 2 Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 11. Tier 2 Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 12. Brazil Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 13. Brazil Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 14. Brazil Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 15. India Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 16. India Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 17. India Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 18. Russia Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 19. Russia Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 20. Russia Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 21. South Africa Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 22. South Africa Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 23. South Africa Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 24. Tier 3 Pharmerging Market by Region (2014 - 2025, USD Billion)
  • 25. Tier 3 Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 26. Tier 3 Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 27. Tier 3 Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 28. Argentina Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 29. Argentina Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 30. Argentina Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 31. Mexico Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 32. Mexico Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 33. Mexico Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 34. Poland Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 35. Poland Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 36. Poland Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 37. Turkey Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 38. Turkey Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 39. Turkey Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 40. Saudi Arabia Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 41. Saudi Arabia Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 42. Saudi Arabia Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 43. Ukraine Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 44. Ukraine Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 45. Ukraine Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 46. Algeria Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 47. Algeria Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 48. Algeria Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 49. Nigeria Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 50. Nigeria Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 51. Nigeria Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 52. Egypt Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 53. Egypt Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 54. Egypt Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 55. Pakistan Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 56. Pakistan Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 57. Pakistan Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 58. Thailand Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 59. Thailand Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 60. Thailand Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)
  • 61. Indonesia Pharmerging Market by Product (2014 - 2025, USD Billion)
  • 62. Indonesia Pharmerging Pharmaceuticals Market by Type (2014 - 2025, USD Billion)
  • 63. Indonesia Pharmerging Healthcare Products Market by Type (2014 - 2025, USD Billion)

List of Figures

  • FIG. 1 Market summary (USD Million), 2016
  • FIG. 2 Market research process
  • FIG. 3 Information Procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Country Risk Analysis, 2016
  • FIG. 16 Regional market place: Key takeaways
  • FIG. 17 Tier I market, 2014 - 2025
  • FIG. 18 Regional Market Share, 2016
  • FIG. 19 Tier II market, 2014 - 2025
  • FIG. 20 Regional Market Share, 2016
  • FIG. 21 India market, 2014 - 2025
  • FIG. 22 Disease prevalence
  • FIG. 23 Russia market, 2014 - 2025
  • FIG. 24 Brazil market, 2014 - 2025
  • FIG. 25 South Africa market, 2014 - 2025
  • FIG. 26 Tier III market, 2014 - 2025
  • FIG. 27 Regional Market Share, 2016
  • FIG. 28 Argentina market, 2014 - 2025
  • FIG. 29 Mexico market, 2014 - 2025
  • FIG. 30 Poland market, 2014 - 2025
  • FIG. 31 Turkey market, 2014 - 2025
  • FIG. 32 Saudi Arabia market, 2014 - 2025
  • FIG. 33 Algeria market, 2014 - 2025
  • FIG. 34 Thailand market, 2014 - 2025
  • FIG. 35 Indonesia market, 2014 - 2025
  • FIG. 36 Egypt market, 2014 - 2025
  • FIG. 37 Nigeria market, 2014 - 2025
  • FIG. 38 Ukraine market, 2014 - 2025
  • FIG. 39 Pakistan market, 2014 - 2025
  • FIG. 40 Strategy framework
Back to Top